Advertisement
YOU ARE HERE: LAT HomeCollectionsRoussel Uclaf Sa
IN THE NEWS

Roussel Uclaf Sa

FEATURED ARTICLES
NEWS
March 15, 1990 | JANNY SCOTT, TIMES MEDICAL WRITER
California Atty. Gen. John K. Van de Kamp called on the state health department Wednesday to allow testing of the abortion pill RU 486 by researchers or drug companies interested in distributing the drug within the state. Van de Kamp, a candidate for the Democratic gubernatorial nomination, called for testing of RU 486 under a 2-year-old program in which the health department has been overseeing the testing of experimental AIDS drugs without the usual federal approval.
ARTICLES BY DATE
BUSINESS
December 12, 1996 | Times Staff and Wire Reports
German chemical producer Hoechst is consolidating its international drug business by buying the rest of France's Roussel Uclaf, the developer of the abortion pill RU-486. Hoechst, which owns more than 56% of Roussel, said it will buy out the remaining stake for $3.62 billion. Hoechst has been reorganizing its drug division, Hoechst Marion Roussel, since acquiring U.S. drug maker Marion Merrell Dow Inc. last year.
Advertisement
NEWS
March 16, 1990 | ROBERT A. JONES
Initially, the scene looks like any other political boogie in a dull election year: Atty. Gen. John K. Van de Kamp, running for governor, stands up and says he wants the drug RU 486 tested in California. OK, John. RU 486 is the abortion pill and this move just might drain some of the female vote away from front-runner Dianne Feinstein. As a maneuver, it has a weary quality.
NEWS
May 17, 1994 | WILLIAM J. EATON, TIMES STAFF WRITER
In a move designed to speed U.S. development of the RU-486 abortion pill, the French manufacturer donated its patent rights to a nonprofit group Monday, with a view toward clinical trials and licensing of the drug in the United States by 1996. Roussel-Uclaf gave its patent rights to the Population Council, an international nonprofit organization engaged in scientific research. The council will conduct the tests and select an American company to produce the abortion pill.
NEWS
March 3, 1994 | D'JAMILA SALEM, TIMES STAFF WRITER
Six years after the controversial RU-486 abortion pill was legalized in France, a New York-based population research group and Roussel Uclaf, the drug's manufacturer, are engaged in negotiations to allow testing and distribution of the drug in the United States. The Population Council, a nonprofit organization devoted to improving access to birth control, is "engaged in active, high-level, negotiations with Roussel on a daily basis,' said Sandra Waldman, a spokeswoman for the organization.
NEWS
March 8, 1990 | From United Press International
In findings hailed as the most definitive evidence yet that the French "abortion pill" is safe and effective, researchers Wednesday released the results of the largest study to date of the controversial drug. The drug RU 486 produced a 96% success rate among 2,115 women in France without causing side effects such as pain or profuse bleeding more frequently than conventional abortions. The study, published in The New England Journal of Medicine, confirms earlier smaller studies.
NEWS
April 21, 1993 | MARLENE CIMONS, TIMES STAFF WRITER
Breaking a longstanding impasse over whether the controversial abortion pill RU-486 will ever be available in the United States, its French manufacturer has agreed to license the drug to a New York-based scientific research organization for eventual distribution in this country, the Food and Drug Administration announced Tuesday. The agreement between the pill maker, Roussel-Uclaf, and the Population Council will enable the U.S.
BUSINESS
December 12, 1996 | Times Staff and Wire Reports
German chemical producer Hoechst is consolidating its international drug business by buying the rest of France's Roussel Uclaf, the developer of the abortion pill RU-486. Hoechst, which owns more than 56% of Roussel, said it will buy out the remaining stake for $3.62 billion. Hoechst has been reorganizing its drug division, Hoechst Marion Roussel, since acquiring U.S. drug maker Marion Merrell Dow Inc. last year.
BUSINESS
February 26, 1993 | From Times Staff and Wire Reports
FDA Discusses Approval of Abortion Pill: The Food and Drug Administration is working with France's Roussel-Uclaf on plans to license and manufacture the controversial RU-486 abortion pill in the United States, an agency spokesman said. Company officials met with FDA Commissioner David Kessler this week and said they were interested in selling the product in the United States.
NEWS
October 29, 1988 | RONE TEMPEST, Times Staff Writer
Health Minister Claude Evin on Friday ordered a French pharmaceutical company to resume distribution of an abortion pill that the company had withdrawn from the market two days earlier under pressure from anti-abortion forces. A Ministry of Health statement said that Evin, citing a 1975 law giving French women the right to voluntary abortion, had acted "with the interests of public health in mind."
NEWS
March 3, 1994 | D'JAMILA SALEM, TIMES STAFF WRITER
Six years after the controversial RU-486 abortion pill was legalized in France, a New York-based population research group and Roussel Uclaf, the drug's manufacturer, are engaged in negotiations to allow testing and distribution of the drug in the United States. The Population Council, a nonprofit organization devoted to improving access to birth control, is "engaged in active, high-level, negotiations with Roussel on a daily basis,' said Sandra Waldman, a spokeswoman for the organization.
NEWS
April 21, 1993 | MARLENE CIMONS, TIMES STAFF WRITER
Breaking a longstanding impasse over whether the controversial abortion pill RU-486 will ever be available in the United States, its French manufacturer has agreed to license the drug to a New York-based scientific research organization for eventual distribution in this country, the Food and Drug Administration announced Tuesday. The agreement between the pill maker, Roussel-Uclaf, and the Population Council will enable the U.S.
BUSINESS
February 26, 1993 | From Times Staff and Wire Reports
FDA Discusses Approval of Abortion Pill: The Food and Drug Administration is working with France's Roussel-Uclaf on plans to license and manufacture the controversial RU-486 abortion pill in the United States, an agency spokesman said. Company officials met with FDA Commissioner David Kessler this week and said they were interested in selling the product in the United States.
NEWS
August 11, 1990 | RONE TEMPEST, TIMES STAFF WRITER
Annie, a 29-year-old secretary in an import-export business, already had two young children from a marriage that ended in divorce. "If I have another child, I want it to be with someone I have truly chosen," she said resolutely. "It's the mother who takes charge of the children." Chantal, 23, a dressmaker from the French Caribbean island of Martinique, said she did not know her boyfriend well enough to have his baby.
NEWS
April 22, 1990
1970: Dr. Etienne-Emile Baulieu and his research team discover receptors within uterine cells that interact with the hormone progesterone. They recognize this knowledge might lead to new methods of fertility control. 1980: The Baulieu research team at Roussel-Uclaf, a Paris-based drug company, creates an "anti-hormone" that blocks the progesterone necessary to sustain pregnancy. The steroid is named RU-38486: RU for Roussel-Uclaf and 38486, the number assigned by the firm.
NEWS
April 22, 1990 | BETH ANN KRIER, TIMES STAFF WRITER
Psychic Makes Baby Vanish Before Birth --Front-page headline in the Sun, a tabloid PRO RU-486 is the most exciting new drug we've had in fertility control since the development of the birth control pill three decades ago. It opens entire new vistas, with benefits far beyond reproductive medicine, ranging from treatment of endometriosis to breast cancer." Dr. David A. Grimes USC School of Medicine CON "There will be serious resistance to RU-486.
NEWS
April 22, 1990
1970: Dr. Etienne-Emile Baulieu and his research team discover receptors within uterine cells that interact with the hormone progesterone. They recognize this knowledge might lead to new methods of fertility control. 1980: The Baulieu research team at Roussel-Uclaf, a Paris-based drug company, creates an "anti-hormone" that blocks the progesterone necessary to sustain pregnancy. The steroid is named RU-38486: RU for Roussel-Uclaf and 38486, the number assigned by the firm.
NEWS
May 17, 1994 | WILLIAM J. EATON, TIMES STAFF WRITER
In a move designed to speed U.S. development of the RU-486 abortion pill, the French manufacturer donated its patent rights to a nonprofit group Monday, with a view toward clinical trials and licensing of the drug in the United States by 1996. Roussel-Uclaf gave its patent rights to the Population Council, an international nonprofit organization engaged in scientific research. The council will conduct the tests and select an American company to produce the abortion pill.
NEWS
April 22, 1990 | BETH ANN KRIER
She was one of the last women in the United States to take RU-486, the French abortion pill. Five weeks pregnant, and having had twins born just 11 months before, she eagerly swallowed three M & M-sized tablets early this year at the only North American site for RU-486 abortion research: Los Angeles County-USC Medical Center's Women's Hospital. Her decision was based almost completely on fear. "I was terrified of a surgical abortion.
NEWS
March 16, 1990 | ROBERT A. JONES
Initially, the scene looks like any other political boogie in a dull election year: Atty. Gen. John K. Van de Kamp, running for governor, stands up and says he wants the drug RU 486 tested in California. OK, John. RU 486 is the abortion pill and this move just might drain some of the female vote away from front-runner Dianne Feinstein. As a maneuver, it has a weary quality.
Los Angeles Times Articles
|